In a notable legal confrontation in the pharmaceutical sector, Sandoz, the generics arm of Novartis, has successfully defended itself against an intellectual property claim made by Astellas – a Japan-based global pharmaceutical company. Astellas has been repelled in its efforts to invalidate one of Sandoz’s UK patents related to the treatment of overactive bladder syndrome. Moreover, Astellas was unable to convince a judge that Sandoz’s product would violate its intellectual property.
Sandoz’s victory in the courtroom marks an important point in the ongoing competition within the intimate and often litigious world of pharmaceutical patents. This case once again spotlights the battles between brand-name drug manufacturers and generic firms, confirming the complexity of intellectual property rights within the world of pharmaceuticals.
Further details on this legal battle involving Sandoz and Astellas can be found via Law360.